DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
77.1 EUR
-0.08 (-0.1%)
Taking everything into account, BSN scores 4 out of 10 in our fundamental rating. BSN was compared to 58 industry peers in the Food Products industry. Both the profitability and the financial health of BSN get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BSN has a Return On Assets (4.20%) which is in line with its industry peers.
BSN's Return On Equity of 11.59% is fine compared to the rest of the industry. BSN outperforms 62.07% of its industry peers.
BSN's Return On Invested Capital of 6.83% is fine compared to the rest of the industry. BSN outperforms 60.34% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.46%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
With a decent Profit Margin value of 6.72%, BSN is doing good in the industry, outperforming 70.69% of the companies in the same industry.
BSN's Profit Margin has been stable in the last couple of years.
The Operating Margin of BSN (13.25%) is better than 79.31% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
The Gross Margin of BSN (50.47%) is better than 79.31% of its industry peers.
BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
BSN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BSN has less shares outstanding
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.54 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
BSN has a better Altman-Z score (2.54) than 63.79% of its industry peers.
BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
BSN's Debt to FCF ratio of 5.07 is fine compared to the rest of the industry. BSN outperforms 70.69% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 67.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.54 |
ROIC/WACC1.05
WACC6.51%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 74.14% of its industry peers.
BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.78, BSN perfoms like the industry average, outperforming 44.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
Measured over the past years, BSN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.17% on average per year.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
The Earnings Per Share is expected to grow by 6.84% on average over the next years.
The Revenue is expected to grow by 3.24% on average over the next years.
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.61, the valuation of BSN can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BSN indicates a slightly more expensive valuation: BSN is more expensive than 62.07% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.13, BSN is valued a bit cheaper.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.60.
Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than the industry average as 63.79% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, BSN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.61 | ||
| Fwd PE | 18.6 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.31 | ||
| EV/EBITDA | 11.07 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.7
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y7.31%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.78%.
BSN's Dividend Yield is a higher than the industry average which is at 3.52.
Compared to an average S&P500 Dividend Yield of 2.39, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
FRA:BSN (11/5/2025, 7:00:00 PM)
77.1
-0.08 (-0.1%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.54B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target79.17 (2.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.38%
PT rev (3m)4.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.61 | ||
| Fwd PE | 18.6 | ||
| P/S | 1.92 | ||
| P/FCF | 18.31 | ||
| P/OCF | 13.66 | ||
| P/B | 3.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.07 |
EPS(TTM)3.74
EY4.85%
EPS(NY)4.14
Fwd EY5.38%
FCF(TTM)4.21
FCFY5.46%
OCF(TTM)5.64
OCFY7.32%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.7
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.54 |
F-Score8
WACC6.51%
ROIC/WACC1.05
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.86%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 4 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 20.61 and the Price/Book (PB) ratio is 3.31.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.65% in the next year.